EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Kevin Miller, Hamza Hashmi, Sridevi Rajeeve

Frontiers in Oncology · 10.05.2024 · 14

DOI: 10.3389/fonc.2024.1398902 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 10.05.2024. Verfasst von Kevin Miller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), which is expressed on the surface of malignant plasma cells. Despite deep initial responses in most patients, relapse after anti-BCMA CAR T cell therapy is common. Investigations of acquired resistance to anti-BCMA CAR T cell therapy are underway. Meanwhile, other viable antigenic targets are being pursued, including G protein-coupled receptor class C group 5 member D (GPRC5D), signaling lymphocytic activation molecule family member 7 (SLAMF7), and CD38, among others. CAR T cells targeting these antigens, alone or in combination with anti-BCMA approaches, appear to be highly promising as they move from preclinical studies to early phase clinical trials. This review summarizes the current data with novel CAR T cell targets beyond BCMA that have the potential to enter the treatment landscape in the near future.

Schlagwörter

Stichwörter der Autor:innen

CAR T cell therapychimeric antigen receptorimmunotherapymultiple myelomanon-BCMA

Autor:innen und Institutionen

  • Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Miller, K., Hashmi, H., & Rajeeve, S. (2024). Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1398902

Vancouver

Miller K, Hashmi H, Rajeeve S. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1398902

BibTeX
@article{Miller2024,
  author = {Miller, Kevin and Hashmi, Hamza and Rajeeve, Sridevi},
  title = {Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1398902}
}
Kostenlos starten →